The rise of Sildenafil initially fueled a period of growth for pharma, nevertheless recent changes present a uncertain scenario for investors. Lower-cost alternatives are reducing earnings, and ongoing litigation add further difficulty to the landscape. While specific companies might still see gains from adjacent offerings, the general trend sugges